[Form 4] GUIDEWIRE SOFTWARE, INC. Insider Trading Activity

Rhea-AI Filing Summary

Fate Therapeutics (FATE) filed a Form 144 disclosing a proposed sale of 9,037 common shares through Fidelity Brokerage Services on the NASDAQ. The shares have an estimated aggregate market value of $9,572.89 based on the filing and represent roughly 0.008% of the company’s 114,633,022 shares outstanding. The filer intends to execute the sale on or about 08/04/2025.

The securities were acquired on 08/01/2025 via restricted-stock vesting classified as compensation from the issuer. No other sales have been reported by the filer in the past three months. By signing, the filer certifies awareness of no undisclosed material adverse information about Fate Therapeutics.

Insights

Securities Analyst

TL;DR: Small Form 144 sale (<0.01% O/S); insignificant to float, neutral signal.

The filing details a routine disposal of 9,037 shares worth about $9.6k. Relative to Fate Therapeutics’ 114.6 million share base, the impact on supply or market perception is negligible. No pattern of recent selling is disclosed, and the shares stem from recent compensation-related vesting, a common liquidity event. Absent further insider activity or material disclosures, the transaction does not alter the investment thesis.

Corporate Governance Expert

TL;DR: Standard Rule 144 notice; governance and disclosure obligations met.

Form 144 demonstrates procedural compliance with SEC Rule 144, confirming the filer’s intent and representation of no undisclosed adverse data. The small size and transparent timing reduce governance or signaling concerns. Investors should nevertheless monitor additional filings for patterns of insider disposition that might indicate strategic shifts or liquidity needs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mullen John P

(Last) (First) (Middle)

C/O GUIDEWIRE SOFTWARE, INC.

970 PARK PL, SUITE 200

(Street)

SAN MATEO CA 94403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guidewire Software, Inc. [ GWRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/01/2025		S(1)		3,000	D	$223.28	143,489	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Automatic sale pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person on October 15, 2024.

Remarks:

	By: Winston King, Attorney-in-Fact for John P. Mullen	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Fate Therapeutics (FATE) shares are covered by this Form 144?

The filing covers 9,037 common shares to be sold.

What is the estimated value of the shares being sold?

The aggregate market value stated is $9,572.89.

When is the planned sale date for these FATE shares?

The filer lists an approximate sale date of 08/04/2025.

How were the shares acquired by the filer?

They were acquired on 08/01/2025 through restricted-stock vesting as compensation.

What percentage of Fate Therapeutics’ total shares does this sale represent?

About 0.008% of the 114,633,022 shares outstanding.